Amendment: SEC Form SC 13G/A filed by BiomX Inc.

$PHGE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $PHGE alert in real time by email
SC 13G/A 1 tm2428335d1_sc13ga.htm SC 13G/A

 

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

 

(Amendment No.  1)*

 

BiomX Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

09090D301

(CUSIP Number)

 

AMR Action Fund, L.P.
c/o AMR Action Fund GP, LLC

225 Franklin Street, Suite 1750
Boston, MA 02110
Tel 862-325-3580

 

With a copy to:

 

Derek Stoldt

Arnold & Porter Kaye Scholer LLP

250 West 55th Street

New York, NY 10019

Tel 212-836-8000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

September 30, 2024

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ¨ Rule 13d-1(b)

 

  x Rule 13d-1(c)

 

  ¨ Rule 13d-1(d)

 

  * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 09090D301 13G Page 2 of 10 Pages

1.

NAMES OF REPORTING PERSON

 

AMR Action Fund, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(See Instructions)

 

(a) ¨

(b) x

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

876,888(1)

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

876,888(1)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

876,888(1)

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)

 

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

4.9%

12.

TYPE OF REPORTING PERSON (see instructions)

 

PN

 

(1) The number of shares of Common Stock beneficially owned by the Reporting Person does not include an aggregate of (i) 3,662,300 shares of Common Stock underlying 36,623 shares of Series X Preferred Stock convertible into Common Stock (subject to a beneficial ownership limitation) and (ii) 1,514,566 shares of Common Stock underlying warrants exercisable for Common Stock (subject to a beneficial ownership limitation).

 

 

 

 

CUSIP No. 09090D301 13G Page 3 of 10 Pages

1.

NAMES OF REPORTING PERSON

 

AMR Action Fund GP, LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)

 

(a) ¨

(b) x

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER


876,888(2)

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER


876,888(2)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

876,888(2)

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)

 

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

4.9%

12.

TYPE OF REPORTING PERSON (see instructions)

 

OO

 

(2) Consists of shares of Common Stock held by AMR Action Fund, L.P. See Footnote 1.

 

 

 

 

CUSIP No. 09090D301 13G Page 4 of 10 Pages

1.

NAMES OF REPORTING PERSON

 

AMR Action Fund, SCSp

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)

 

(a) ¨

(b) x

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Luxembourg

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER


876,888(3)

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER


876,888(3)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

876,888(3)

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)

 

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

4.9%

12.

TYPE OF REPORTING PERSON (see instructions)

 

PN

 

(3) The number of shares of Common Stock beneficially owned by the Reporting Person does not include an aggregate of (i) 3,662,300 shares of Common Stock underlying 36,623 shares of Series X Preferred Stock convertible into Common Stock (subject to a beneficial ownership limitation) and (ii) 1,514,566 shares of Common Stock underlying warrants exercisable for Common Stock (subject to a beneficial ownership limitation).

 

 

 

 

CUSIP No. 09090D301 13G Page 5 of 10 Pages

1.

NAMES OF REPORTING PERSON

 

AMR Action Fund GP, S.a.r.l.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)

 

(a) ¨

(b) x

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Luxembourg

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER


876,888(4)

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER


876,888(4)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

876,888(4)

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)

 

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

4.9%

12.

TYPE OF REPORTING PERSON (see instructions)

 

OO

 

(4) Consists of shares of Common Stock held by AMR Action Fund, SCSp. See Footnote 3.

 

 

 

 

Item 1.

 

(a)

Name of Issuer

BiomX Inc.

   
(b)

Address of Issuer’s Principal Executive Offices
708 Quince Orchard Rd, Suite 205

Gaithersburg, MD 20878

 

Item 2.

 

(a) Name of Person Filing:

 

This Amendment is being filed by each of:

 

(i) AMR Action Fund, L.P.;

 

(ii) AMR Action Fund GP, LLC;

 

(iii) AMR Action Fund, SCSp; and

 

(iv) AMR Action Fund GP, S.a.r.l.

 

(each a “Reporting Person” and, collectively, the “Reporting Persons”).

 

(b)

Address of Principal Business Office or, if None, Residence:

 

The principal business office of each of the Reporting Persons are:

 

AMR Action Fund, L.P., c/o AMR Action Fund GP, LLC, 225 Franklin Street, Suite 1750, Boston, MA 02110

AMR Action Fund GP, LLC, 225 Franklin Street, Suite 1750, Boston, MA 02110

AMR Action Fund, SCSp, c/o AMR Action Fund GP, S.a.r.l., 16 Rue Eugene Ruppert, L-2543 Luxembourg, Grand Duchy of Luxembourg

AMR Action Fund GP, S.a.r.l., 16 Rue Eugene Ruppert, L-2543 Luxembourg, Grand Duchy of Luxembourg

 

(c)

Citizenship:


AMR Action Fund GP, S.a.r.l., and AMR Action Fund, SCSp are organized under the laws of Luxembourg. AMR Action Fund GP, LLC and AMR Action Fund, L.P. are organized under the laws of the State of Delaware.

   
(d)

Title of Class of Securities

 

Common Stock, par value $0.0001 per share (the “Shares”)

   
(e)

CUSIP Number

 

09090D301

 

 

 

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
     
(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
(e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
(f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
(g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
(h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
(j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
     
(k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

 

Not applicable.

 

Item 4. Ownership.

 

Item 4 is hereby amended in its entirety as follows:

 

(a) (b) Number and percentage of Issuer Shares beneficially owned by each Reporting Person:

 

Reporting Person  Number of Shares   Percentage of Class 
AMR Action Fund, L.P.   876,888    4.9%
AMR Action Fund GP, LLC   

876,888

    

4.9

%
AMR Action Fund, SCSp   876,888    4.9%
AMR Action Fund GP, S.a.r.l.   

876,888

    

4.9

%

 

With respect to each of the Reporting Persons:

 

(a) Number of shares as to which the Reporting Person has:
     
  (i)

Sole power to vote or to direct the vote:

AMR Action Fund, L.P.: 0

AMR Action Fund GP, LLC: 0

AMR Action Fund, SCSp: 0

AMR Action Fund GP, S.a.r.l.: 0

 

 

 

 

  (ii)

Shared power to vote or to direct the vote:

AMR Action Fund, L.P.: 876,888

AMR Action Fund GP, LLC: 876,888

AMR Action Fund, SCSp: 876,888

AMR Action Fund GP, S.a.r.l.: 876,888

     
  (iii)

Sole power to dispose or to direct the disposition of:

AMR Action Fund, L.P.: 0

AMR Action Fund GP, LLC: 0

AMR Action Fund, SCSp: 0

AMR Action Fund GP, S.a.r.l.: 0

     
  (iv)

Shared power to dispose or to direct the disposition of:

AMR Action Fund, L.P.: 876,888

AMR Action Fund GP, LLC: 876,888

AMR Action Fund, SCSp: 876,888

AMR Action Fund GP, S.a.r.l.: 876,888

 

The information as of the date of the event which requires filing of this statement required by Items 4(a) - (c) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. AMR Action Fund, L.P. is the record owner of 650,997 shares of Common Stock. AMR Action Fund GP, LLC is the general partner of AMR Action Fund, L.P. and may be deemed to have voting and dispositive control over the shares of Common Stock held by AMR Action Fund, L.P. AMR Action Fund, SCSp is the record owner of 225,891 shares of Common Stock. AMR Action Fund GP, S.a.r.l. is the general partner of AMR Action Fund, SCSp and may be deemed to have voting and dispositive control over the shares of Common Stock held by AMR Action Fund, SCSp. Each of AMR Action Fund GP, LLC and AMR Action Fund GP, S.a.r.l. disclaims beneficial ownership of the shares of Common Stock.

 

Throughout this report, the percentage of outstanding shares of Common Stock beneficially owned by the Reporting Persons reflects 17,895,845 shares of Common Stock as of August 12, 2024, based on the Issuer’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission on August 14, 2024, and the Issuer’s 1-for-10 reverse stock split effective as of August 26, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 16, 2024.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

 

 

 

Item 10. Certification.

 

Each of the Reporting Persons hereby certifies as follows:

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

Dated: November 13, 2024

 

AMR ACTION FUND, L.P.

 

By: AMR Action Fund GP, LLC, its General Partner

 

/s/ Henry Skinner  
Name:  Henry Skinner  
Title: Chief Executive Officer  

 

AMR ACTION FUND GP, LLC

 

/s/ Henry Skinner  
Name:  Henry Skinner  
Title: Chief Executive Officer  

 

AMR ACTION FUND, SCSp

 

By: AMR Action Fund GP, S.a.r.l., its General Partner

 

/s/ Henry Skinner  
Name:  Henry Skinner  
Title: Class A Manager  

 

AMR ACTION FUND GP, S.a.r.l.

 

/s/ Henry Skinner  
Name:  Henry Skinner  
Title: Class A Manager  

 

 

 

 

EXHIBIT INDEX

 

Exhibit    
99.1   Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by AMR Action Fund, L.P., on March 25, 2024).

 

 

 

Get the next $PHGE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PHGE

DatePrice TargetRatingAnalyst
11/16/2021$16.00 → $13.00Buy
Chardan Capital
10/19/2021$28.00 → $16.00Buy
Chardan Capital
10/18/2021$20.00 → $10.00Buy
HC Wainwright & Co.
More analyst ratings

$PHGE
Press Releases

Fastest customizable press release news feed in the world

See more
  • BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

    NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

    BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

    In February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b study of BX004; topline results anticipated in Q1 2026Topline Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) expected by end of March 2025Initiated exploration and analysis of real-world evidence in people with Cystic Fibrosis (CF) on the relationship between Pseudomonas aeruginosa reduction and clinical outcomes, ahead of expected regulatory discussions in second half of 2025 NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE, the "Company" or "BiomX")), a clinical-stage company advancing novel natural

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PHGE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PHGE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PHGE
SEC Filings

See more

$PHGE
Leadership Updates

Live Leadership Updates

See more
  • BiomX Announces the Appointment of Susan Blum to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

    $PHGE
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Telum Therapeutics appoints Dr. Subhendu Basu as CEO

    Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PHGE
Financials

Live finance-specific insights

See more
  • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

    BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

    NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company's website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expec

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

    BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now expected to report topline results in H1 2026 following resolved manufacturing delays Company to host conference call and webcast today at 8:00AM ET NESS ZIONA, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE, the "Company" or "BiomX")), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announces financial results for its third quarter ended September 30, 2024, and provide

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PHGE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more